Target motion mitigation promotes high-precision treatment planning and delivery of extreme hypofractionated prostate cancer radiotherapy: Results from a phase II study.
Greco C, Pares O, Pimentel N, Louro V, Morales J, Nunes B, Vasconcelos AL, Antunes I, Kociolek J, Stroom J, Viera S, Mateus D, Cardoso MJ, Soares A, Marques J, Freitas E, Coelho G, Fuks Z.
Greco C, et al. Among authors: stroom j.
Radiother Oncol. 2020 May;146:21-28. doi: 10.1016/j.radonc.2020.01.029. Epub 2020 Feb 19.
Radiother Oncol. 2020.
PMID: 32087469
Clinical Trial.